GBIO
Generation Bio
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About GBIO
Generation Bio Co.
A biotechnology company that develops gene therapies for the treatment of liver and retina diseases
301 Binney Street, Cambridge, Massachusetts 02142
--
Generation Bio Co. was established on October 21, 2016. The company is an innovative genetic medicine company that leverages its proprietary non-viral gene therapy platform to create a new class of gene therapies that provide long-lasting, reusable treatments for millions of patients with rare and endemic diseases. The company's non-viral gene therapy platform integrates high-volume DNA constructs known as closed DNA or ceDNA; the company's cell-targeted lipid nanoparticle delivery system, or ctLNP; and its established, scalable capillar-free manufacturing process. The company is using the company's approach to develop new gene therapies to deliver genetic payloads to a variety of tissues, including a variety of diseases.
Company Financials
EPS
GBIO has released its 2024 Q4 earnings. EPS was reported at -0.32, versus the expected -0.25, missing expectations. The chart below visualizes how GBIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GBIO has released its 2024 Q4 earnings report, with revenue of 4.19M, reflecting a YoY change of 45.52%, and net profit of -21.38M, showing a YoY change of 39.23%. The Sankey diagram below clearly presents GBIO’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
